Fifty-nine samples from patients with metastatic melanoma were assessed for BRAF mutations using IdyllaTM, high resolution amplicon melting (HRM), real-time allele specific amplification (RT-ASA), next generation sequencing (NGS) and immunohistochemistry (IHC). The gene discussed is BRAF; the disease is metastatic melanoma.